Sanofi SA vs Direxion Daily Semiconductor Bear 3X Shares — how do they compare? Sanofi SA trades at $40.04 (market cap $95.18B), while Direxion Daily Semiconductor Bear 3X Shares trades at $34.36 (market cap $1.96B). The key difference: Sanofi SA is far larger — about 48.6× Direxion Daily Semiconductor Bear 3X Shares's market cap, and Sanofi SA pays a 6.01% dividend while Direxion Daily Semiconductor Bear 3X Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Direxion Daily Semiconductor Bear 3X Shares for 11 Days on average.
| SNY | SOXS | |
|---|---|---|
Market Cap | $95.18B | $1.96B |
Volume | 2,995,646 | 113,512,541 |
Sector | Health | Leveraged / Inverse |
52-Week High | $52.34 | $988.00 |
52-Week Low | $39.51 | $29.62 |
Typical Hold Time | 94 Days | 11 Days |
Enterprise Value | $114.48B | — |
Dividend Yield | 6.01% | — |
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
SOXS, the Direxion Daily Semiconductor Bear 3X ETF, is trading at $34.39, up 12.22% today, reflecting its inverse leveraged exposure to semiconductor stocks. The technical picture is bearish overall, with moving averages signaling a downtrend. Recent news highlights the fund's volatility and tactical use during semiconductor sector pullbacks, driven by factors like AI demand fluctuations and competitive pressures on chipmakers.
The outlook for SOXS remains highly speculative, suitable only for short-term traders betting against semiconductors. Key risks include the fund's decay from daily rebalancing, reliance on semiconductor volatility, and potential for rapid losses if the sector rallies. Investors should avoid long-term holdings due to structural erosion and elevated volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →SOXS is a leveraged ETF that seeks daily investment results corresponding to 300% of the inverse (opposite) of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bearish (short) position on the semiconductor sector. Due to the effects of compounding and leverage, SOXS is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXS →